Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSSKL1223 is an inhibitor of thioredoxin-interacting protein (TXNIP).1 It inhibits TXNIP promoter activity in a reporter assay using INS-1 cells expressing human TXNIP (IC50 = 0.64 µM) and decreases the levels of TXNIP in the same cells in a concentration-dependent manner. SKL1223 (5 or 20 µM) induces glucagon secretion from TC-1 mouse lung cancer cells and decreases glucagon-induced glucose production in primary mouse hepatocytes. It decreases fasting blood levels of glucose, serum levels of glucagon and triglycerides, and hepatic levels of triglycerides in mice when administered at a dose of 70 mg/kg per day. SKL1223 decreases blood levels of glucose and serum levels of glucagon in db/db mice but not in Txnip-/- mice.
WARNING This product is not for human or veterinary use.
1. Orally available small molecule regulates TXNIP expression and glucagon action for the treatment of diabetes. Research Square (2024).